Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors

Erik Hedrick, Xi Li and Stephen Safe

Department of Veterinary Physiology & Pharmacology, Texas A&M University, College Station, TX 77843 USA

Running Title: Penfluridol anticancer activity is ROS-dependent

Keywords: penfluridol; ROS; integrin; Sp proteins; NR4A1

Abbreviations: C-DIM8, 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane; C-DIM14, 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane; DIM-C-pPhCO₂Me, 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane; DIM-C-pPhOH, 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane; FAK, focal adhesion kinase; GSH, glutathione; NAC, N-acetylcysteine; NR4A1, nuclear receptor 4A1; NSAIDs, non-steroidal anti-inflammatory drugs; PEITC, phenethylisothiocyanate; PP2A, protein phosphatase 2A; RMS, rhabdomyosarcoma; ROS, reactive oxygen species; Sp1, specificity protein 1; TFs, transcription factors; VEGF, vascular endothelial growth factor

Funding: The financial assistance of the National Institutes of Health (P30-ES023512, S. Safe), Texas AgriLife Research and Sid Kyle endowment, is gratefully acknowledged.

To whom correspondence should be addressed:
Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, College Station, TX 77843-4466 USA, Tel: 979-845-5988/Fax: 979-862-4929, Email: ssafe@cvm.tamu.edu

Conflict of Interest: There are no conflicts of interest to declare.

Word Count: 4447 words
Figures: 7 figures
Table: 0 tables
ABSTRACT

It was recently demonstrated that penfluridol inhibited breast tumor growth and metastasis and this was associated with downregulation of α6- and β4-integrins. In this study, we observed the penfluridol induced reactive oxygen species (ROS) and this was the primary mechanism of action. Penfluridol-mediated growth inhibition, induction of apoptosis, and inhibition breast cancer cell migration was attenuated after cotreatment with glutathione (GSH). Penfluridol also downregulated Sp transcription factors Sp1, Sp3 and Sp4 through epigenetic downregulation of cMyc and cMyc-regulated microRNAs (miR-27a and miR-20a/miR-17) and induction of the miR-regulated Sp transcriptional repressors ZBTB10 and ZBTB4. α6- and β4-Integrins as well as α5- and β1-integrin are Sp-regulated genes that are also coregulated by the orphan nuclear receptor NR4A1 and these integrins can be targeted by agents such as penfluridol that suppress Sp1, Sp3 and Sp4 and also by NR4A1 antagonists.
INTRODUCTION

Repositioning clinically-approved drugs for cancer chemotherapy has several advantages including a more rapid drug approval process coupled with potential development of mechanism-based compounds that can be clinically used to target important pro-oncogenic pathways. This approach has been particularly successful with non-steroidal antiinflammatory drugs (NSAIDs) and antidiabetics such as metformin (1,2). Phenothiazine-derived antipsychotic drugs such as thioridazine and chlorpromazine exhibit anticarcinogenic activity in several different cancer cell lines (3-9). More recent studies have demonstrated that penfluridol, another antipsychotic drug, also inhibits breast and pancreatic cancer cell growth (9,10). For example, in pancreatic cancer a series of phenothiazene analogs induced apoptosis and inhibited clonogenic growth and colony formation, and more detailed studies with penfluridol indicated that induction of protein phosphatase 2A (PP2A) was a key effect of this compound (9). Penfluridol exhibited antimetastatic activity in triple negative breast cancer cells and inhibited tumor growth and brain metastasis in three different in vivo models and the key elements were inhibition of α6- and β4-integrin expression (10). However, the mechanisms of the penfluridol-induced responses were not well defined, and this limits potential clinical applications of the compound.

Recent studies in this laboratory showed that β1- and β3-integrin expression in breast cancer cells is regulated by specificity protein 1 (Sp1) transcription factor (TF) in combination with the orphan nuclear receptor 4A1 (NR4A1, Nur77, TR3) which acts as a nuclear cofactor (11). Many of the effects observed in breast and other cancer cell lines treated with penfluridol and other phenothiazine derivatives are similar to that
observed after knockdown of Sp transcription factors Sp1, Sp3 or Sp4 or after treatment with agents that target Sp TFs (10-18). For example, knockdown of Sp1, Sp3 or Sp4 individually or combined decreased proliferation and migration/invasion of breast (MDA-MB-231 and SKBR3) and other cancer cell lines (12) and similar results were observed for drugs that repress Sp TF expression (13-18). Moreover, the effects of penfluridol and other phenothazines on inhibition of several genes including cyclin D1, bcl-2, vascular endothelial growth factor (VEGF) receptors, myc and activation/cleavage caspase-3/PARP (3-10) have also been observed after Sp knockdown (10-18). It was recently reported that the antimetastatic activity of penfluridol in triple negative breast cancer cells was related to downregulation of α6- and β4-integrin expression (10); however, since both integrin gene promoters are GC-rich, it is possible that Sp1 and other Sp TFs may regulate expression of α6- and β4-integrins as well as α5-integrin (19-21).

Therefore, we hypothesize that the mechanism of action of penfluridol as an antimetastatic agent for triple negative breast cancer is due to downregulation of Sp TFs. This hypothesis was confirmed in this study which shows that penfluridol induces reactive oxygen species (ROS) in breast cancer cells and ROS-dependent downregulation of Sp1, Sp3 and Sp4 and Sp-dependent genes including α6-, α5-, β1- and β4-integrins which are also coregulated by NR4A1 and decreased by NR4A1 antagonists.
MATERIALS AND METHODS

Cell lines and antibodies. Breast cancer (SKBR3, MDA-MB-231) cell lines were purchased from American Type Culture Collection (Manassas, VA) and were kept frozen until initiation of these studies. The cells were received at low passage (<15) and new frozen stocks were used every 6-8 weeks. The two cell lines were authenticated by Biosynthesis (Lewisville, TX, USA) on February 3, 2015. Cells were maintained 37°C in the presence of 5% CO₂ in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium with 10% fetal bovine serum with antibiotic. Dulbecco’s Modified Eagle’s Medium was purchased from GenDepot (Barker, TX). Penfluridol, N-acetylcysteine (NAC), catalase and 36% formaldehyde were purchased from Sigma-Aldrich (St. Louis, MO). Glutathione (GSH) reduced free acid was purchased from Millipore (Temecula, CA). Hematoxylin was purchased from Vector Laboratories (Burlingame, CA). Apoptotic, Necrotic, and Healthy Cells Quantification Kit was purchased from Biotium (Hayward, CA). Antibodies were purchased as outlined in Supplementary Table 1.

Cell proliferation, luciferase and ROS assays and Annexin V staining. Cell proliferation and ROS assays using the cell permeable fluorescent CM-H3DCFDA probe were carried out as described previously (11-13) (also see Supplemental Methods), and changes in cell number were determined by Coulter Z1 cell counter. Annexin V staining used the Vybrant apoptosis kit according to the manufacturer’s protocol. The GC-rich promoter luciferase pGL3-pGC3-luc construct and transfection/luciferase assays were carried out as previously described (22).

Boyden chamber assay. SKBR3 and MDA-MB-231 cancer cells (3.0 x 10⁵ per well) were seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium
supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 hr. Cells were seeded and subsequently treated with varying concentrations of penfluridol for 24 hr (± GSH, 3 hr prior to treatment) and for subsequent 24 hr of cotreatment. Cells were trypsinized, counted, placed in 12-well 8.0 μm pore ThinCerts from Greiner Bio-one (Monroe, NC), allowed to migrate for 24 hr, fixed with formaldehyde, and then stained with hematoxylin. Equal numbers of cells were used for each assay and cells that migrated through the pores were then counted as described (11-13).

**RT-PCR.** miRNA was isolated using the mirVana miRNA isolation kit (Ambion, Austin, TX) according to the manufacturer's protocol. Quantification of miRNA (RNU6B and miR-17, miR-20a, and miR-27a) was done using the TaqMan miRNA assay kit (Life Technologies) according to the manufacturer's protocol with real-time PCR. U6 small nuclear RNA was used as a control to determine relative miRNA expression.

**Western blot analysis.** SKBR3 and MDA-MB-231 cancer cells (3.0 x 10^5 per well) were seeded in Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped fetal bovine serum and were allowed to attach for 24 hr. Cells were treated with varying doses of penfluridol for 24 hr. Cells were analyzed by western blot as described previously (11-13) and the catalase inhibition studies were determined as described (17).

**Small interfering RNA interference assay.** siRNAs used are outlined in Supplementary Table 1. SiRNA experiments were conducted as described previously (11-13).
Chromatin immunoprecipitation. The chromatin immunoprecipitation (ChIP) assay was performed using the ChIP-IT Express magnetic chromatin immunoprecipitation kit (Active Motif, Carlsbad, CA) according to the manufacturer's protocol. SKBR3 and MDA-MB-231 cells were treated with DMSO, DIM-C-pPhOH (15 or 20 μM), DIM-C-pPhCO₂Me (15 or 20 μM) for 24 hr, or penfluridol (5 μM) for 3 or 6 hr. Cells were then fixed with 1% formaldehyde, and the cross-linking reaction was stopped by addition of 0.125 M glycine. After washing twice with phosphate-buffered saline, cells were scraped and pelleted. Collected cells were hypotonically lysed, and nuclei were collected. Nuclei were then sonicated to the desired chromatin length (∼200 to 1,500 bp). The sonicated chromatin was immunoprecipitated with normal IgG, p300, Sp1, Sp3, Sp4, NR4A1, or RNA polymerase II antibodies and protein A-conjugated magnetic beads at 4°C for overnight. After the magnetic beads were extensively washed, protein-DNA cross-links were reversed and eluted. DNA was prepared by proteinase K digestion followed by PCR amplification. Primers used for detecting PCR products are listed in Supplementary Table 1. PCR products were resolved on a 2% agarose gel in the presence of RGB-4103 GelRed Nucleic Acid Stain.

Xenograft studies. Female athymic nude mice 4-6 weeks old were purchased, and MDA-MB-231 cancer cells (2.0 x10⁶ cells) were suspended in Matrigel (1:1 ratio) and injected into the mammary fat pad of athymic nude mice. When tumors became palpable (150-200 mm³), mice were randomly assigned to control (corn oil vehicle) and penfluridol (10 mg/kg/day), and then treated every day for 19 days. Tumor volumes, tumor weights, and tumor lysates were determined and analyzed as previously described (13,14).
Statistical analysis. Statistical significance of differences between the treatment groups was determined as previously described (11-13).
RESULTS

Drugs that downregulate Sp TFs act through ROS-dependent and -independent pathways (18), and results in Figure 1A show that different concentrations of penfluridol induced ROS in MDA-MB-231 and SKBR3 cells after treatment for 3 and 6 hr and similar results were observed after 24 hr (Suppl. Fig. S1A). Moreover, after cotreatment with 5 mM GSH, the penfluridol-mediated induction of ROS as detected using the fluorescent probe CM-H$_2$DCFDA was significantly attenuated. The role of penfluridol-induced ROS on cell proliferation (Fig. 1B), Annexin V staining (apoptosis) (Fig. 1C), and migration in a Boyden chamber assay (Fig. 1D) was also determined in MDA-MB-231 and SKBR3 cells treated with penfluridol alone and in combination with GSH. Penfluridol inhibited cell growth and induced Annexin V staining; however, we now show for the first time that all of these responses were ROS-dependent and significantly attenuated after cotreatment with GSH. SKBR3 cells appeared to be more resistant to penfluridol than MDA-MB-231 cells and this may be due to several factors including constitutive ROS levels, GSH and reductant levels and differential expression of drug-metabolizing and transport enzymes.

Results illustrated in Figures 2A and 2B show that penfluridol decreased expression of Sp1, Sp3 (both high and low molecular weight forms), and Sp4 in MDA-MB-231 and SKBR3 cells and cotreatment with GSH attenuated these effects, and similar results were observed for NAC (Suppl. Fig. S1B). For some responses (e.g. Sp1), addition of GSH or NAC enhanced endogenous expression of these proteins. Penfluridol decreased focal adhesion kinase (FAK) phosphorylation and activated (cleaved) caspase 3 in breast cancer cells (Figs. 2C and 2D) as previously reported (10).
and the responses were attenuated by cotreatment with GSH. Penfluridol also induced ROS-dependent caspase 3/PARP cleavage (apoptosis) in both cell lines (Figs. 2C and 2D). In addition, penfluridol-mediated downregulation of Sp proteins was also inhibited after addition of catalase (Fig. 2E) and penfluridol also decreased luciferase activity in these cells transfected with a construct containing 3 consensus (Sp) binding sites (Fig. 2F), confirming that induction of apoptosis and the growth and migration inhibitory effects of penfluridol in breast cancer cells were ROS-dependent.

**Penfluridol activates the ROS → Myc → miR-27a/miR-20/17a → ZBTB pathway**

Figure 3 illustrates the cascade of events leading to ROS-dependent downregulation of Sp TFs and this is initiated by cMyc downregulation due to rapid shifts of chromatin-modifying complexes from non-GC-rich to GC-rich (e.g. cMyc) gene promoters (13,14,23). Results in Figure 3B show that penfluridol also decreased cMyc expression in MDA-MB-231 and SKBR3 cells and this response was totally reversed after cotreatment with GSH, and Figure 3C shows that cMyc and Sp1 were rapidly decreased in MDA-MB-231 and SKBR3 cells after treatment with penfluridol. ChIP analysis showed that pol II association with the GC-rich cMyc promoter was decreased after treatment of MDA-MB-231 and SKBR3 cells with penfluridol for 3 and 6 hr, and this was accompanied by an increase in the inhibitory H3K27me3 and a decrease in the activating H3K4me4 and H4K16Ac histone marks (Fig. 3D). The ROS-dependent decrease in cMyc was accompanied by a decrease in the cMyc-regulated miR-27a and miR-20a/miR-17 after treatment penfluridol and this decrease was also inhibited after cotreatment with GSH (Fig. 3E). Penfluridol-mediated repression of miR-27a and miR-
20/miR-17 (part of the miR-17-92 cluster) resulted in induction of the miR-regulated Sp repressors ZBTB10 and ZBTB4, respectively, and this induction response was also attenuated in cells cotreated with GSH (Fig. 3F). These results demonstrate that the mechanism of penfluridol-induced ROS is initiated by ROS-mediated epigenetic repression of cMyc (Fig. 3A) and this has previously been observed for phenethylisothiocyanate (PEITC) and HDAC inhibitors in pancreatic cancer and rhabdomyosarcoma (RMS) cells, respectively (13,14).

**Penfluridol induces ROS-dependent repression of integrins**

Penfluridol was reported to decrease $\alpha_6$- and $\beta_4$-integrin in breast cancer cells (10). Our results confirm this same response in MDA-MB-231 and SKBR3 cells, and cotreatment with GSH which attenuated this effect (Fig. 4A) indicating that this response was also ROS-dependent. We also observed that $\alpha_5$- and $\beta_1$-integrin expression were decreased by penfluridol and rescued after cotreatment with GSH (Figs. 4A and 4B) and this was consistent with our recent studies showing that $\beta_1$-integrin is an Sp-regulated gene and $\alpha_5$-integrin appears to be coregulated with $\beta_1$-integrin (11). Confirmation that $\alpha_6$, $\alpha_5$, $\beta_4$- and $\beta_1$-integrin are Sp-regulated genes was determined by RNA interference where knockdown of one or more of Sp1 (siSp1), Sp3 (siSp3), Sp4 (siSp4) or all three Sps (siSp1,3,4) decreased expression of the integrins in MDA-MB-231 (Fig. 4C) and SKBR3 (Fig. 4D) cells. Lysates for this western blot were obtained from a previous study which showed efficient knockdown of Sp1, Sp3 and Sp4 (12). Results of Sp knockdown show that $\alpha_5$- and $\beta_4$-integrins were coregulated by two or all three of the Sp TFs; however, $\alpha_6$-integrin and $\beta_1$-integrin were regulated only by Sp4.
(MDA-MB-231) and Sp1 (SKBR3), respectively. Knockdown of cMyc by RNA decreased Sp1, Sp3 and Sp4 expression in MDA-MB-231 and SKBR3 cells (Fig. 4E), and the same treatment also decreased expression of α6-, α5-, β1- and β4-integrin in the same cell lines (Fig. 4F). Similar results were observed with a second oligonucleotide targeting cMyc (Suppl. Fig. S1C). Thus, penfluridol activation of ROS results in cMyc downregulation, leading to decreased expression of Sp1, Sp3, Sp4 and Sp-regulated genes α6-, α5-, β1- and β4-integrin. The critical role of cMyc was confirmed in studies showing that penfluridol-induced downregulation of Sp proteins, Sp-regulated genes and caspase 3/PARP cleavage was rescued by Myc overexpression (Suppl. Fig. S2). Moreover, similar results were observed after knockdown of ZBTB10 (Suppl. Fig. S3).

Since the α6-, α5-, β1- and β4-integrins are Sp-regulated genes, we also investigated the effects of penfluridol on association of pol II and Sp1, Sp3, Sp4 with the GC-rich regions of the integrin gene promoters (Fig. 5A) using a ChIP assay. In addition, since we previously observed that NR4A1 and p300 act as cofactors for Sp-dependent activation of β1-integrin (11), the effects of penfluridol on their association with the integrin promoters was also determined. Figures 5B-5E show that pol II, Sp1, Sp3, Sp4, p300 and NR4A1 were all associated with the α6-, β4-, α5- and β1-integrin gene promoters as determined in a ChIP assay. With the exception of p300, treatment of MDA-MB-231 and SKBR3 cells with penfluridol decreased association of Sp1, Sp3, Sp4 and NR4A1 with the four integrin promoters, whereas the loss of p300 was promoter- and cell context-dependent.
NR4A1/Sp regulation of integrins

NR4A1/Sp regulate expression of β1- and α5-integrin in breast cancer cells, and knockdown of Sp or NR4A1 or treatment with an NR4A1 antagonist inhibits their expression (11). Therefore, we investigated the activity of penfluridol as an NR4A1 ligand in Panc1 cells transfected with a GAL4-NR4A1 chimera and a reporter gene containing a GAL4 response element; this assay is used for screening NR4A1 antagonists (24,25), and penfluridol did not inhibit or activate this system (Suppl. Fig. S4). Knockdown of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonists 1,1-bis(3'-indolyl)-1-((p-hydroxyphenyl)methane (DIM-C-pPhOH) or 1,1-bis(3'-indolyl)-1-1((p-carbomethoxyphenyl)methane (DIM-C-pPhCO2Me) decreased expression of α6- and β4-integrin in MDA-MB-231 and SKBR3 cells (Fig. 6A) and similar results were previously observed for β1- and α5-integrin (11). Treatment of MDA-MB-231 and SKBR3 cells with DIM-C-pPhOH (C-DIM8) or DIM-C-pPhCO2Me (C-DIM14) showed that these compounds induced loss of pol II from the α6- (Fig. 6C), β4- (Fig. 6D) and α5- (Fig. 6E) integrin promoters in a ChIP assay and this was previously observed for the β1-integrin promoter (11). Unlike penfluridol which decreased expression of Sp1, Sp3 and Sp4, resulting in loss of these TFs from the integrin promoters (Fig. 5), NR4A1 antagonists or NR4A1 knockdown do not affect Sp expression (11) and retention or loss of Sp1, Sp3 or Sp4 from the integrin promoters in ChIP assays is highly variable and gene promoter- and cell context-dependent (11). This variability was observed for p300 (Figs. 6C-6E) and also in a previous study (11). Nevertheless, the results show that both penfluridol and NR4A1 antagonists downregulate expression of α5, α6-, β1- and β-
4 integrin by selectively targeting the Sp and NR4A1 transcription factors, respectively, which are required for expression of the integrin genes (Fig. 6F).

Treatment of athymic nude mice bearing MDA-MB-231 cells in an orthotopic model with penfluridol (10 mg/kg/day) decreased tumor volume over the treatment period (Fig. 7A) and inhibited tumor growth (Fig. 7B), and toxicity (organ damage or weight loss) was not observed. Western blot analysis of lysates from control (solvent) and penfluridol-treated mice showed that penfluridol decreased expression of Sp1, Sp3 and Sp4, prototypical Sp-regulated genes (survivin and EGFR) including α6-, α5-, β1- and β4-integrin and induced apoptosis (Fig. 7C). These effects were also quantitated (Fig. 7D) and penfluridol significantly decreased expression of Sp proteins and Sp-regulated genes or increased caspase 3/PARP cleavage compared to control protein set at 100% and normalized to β-actin. Thus, the in vivo results complement the in vitro studies demonstrating that the anticancer activities of penfluridol are ROS-dependent and this includes NR4A1/Sp-mediated downregulation of integrins.
DISCUSSION

Integrins are cell surface receptors that function as α/β heterodimers which are formed from the 18 α and 8 β subunits, and the functions of the known 24 α/β-integrin heterodimers are highly tissue-/cell type-specific. In cancer cells, integrins are important for migration and invasion, and overexpression of some integrins in cancer patients is a negative prognostic factor (26,27). Integrins play a key role in breast cancer stem cells and mammary tumors, and there is extensive evidence for the role of β1-, β4-, α5- and α6-integrins and their α/β heterodimers in breast cancer cell migration, invasion and metastasis (28-34). Although integrin inhibitors have been developed, their applications for cancer chemotherapy have been limited (26) and this is due, in part, to β1-β3-integrin switching in which drugs targeting β1-integrin induce β3-integrin (35,36). We recently showed that the orphan nuclear receptor NR4A1 regulates expression of β1-integrin and treatment of breast cancer cells with bis-indole-derived (C-DIMs) NR4A1 antagonists such as DIM-C-pPhOH and DIM-C-pPhCO₂Me decrease both β1- and β3-integrin expression and eliminate the switching pathway (11). Both integrins are regulated by an NR4A1-Sp complex which binds to GC-rich regions of their gene promoters (Fig. 6F), suggesting that β1- and β3-integrin can be targeted by NR4A1 antagonists or drugs that target Sp transcription factors.

It was previously reported that penfluridol decreased expression of α6- and β4-integrin in breast cancer cells (10). Since these cell lines highly express Sp1, Sp3 and Sp4 (37) and since there is evidence for Sp-regulation of these integrins (19,20), we hypothesized that the mechanism of action of penfluridol may be due to repression of Sp proteins. We also investigated α5-integrin expression which also has a GC-rich
gene promoter (21). Using SKBR3 and MDA-MB-231 cells as a model, it was clear that penfluridol induced ROS and the resulting inhibition of cell growth and migration and induction of apoptosis were all inhibited after cotreatment with GSH (Fig. 1). Subsequent experiments show that induction of ROS was the key factor in mediating downregulating Sp1, Sp3 and Sp4 through ROS-dependent epigenetic repression of cMyc, decreased expression of cMyc-regulated miR-27a and miR-20a/miR-17, and induction of the Sp repressors ZBTB10 and ZBTB4. This ROS-dependent pathway has previously been observed for other ROS inducers such as PEITC and HDAC inhibitors (13,14). The ROS-miR-ZBTB-Sp pathway (Fig. 3A) has also been observed in cancer cells treated with a nitro-aspirin derivative, celastrol, betulinic acid and curcumin; other ROS inducers including arsenic trioxide, ascorbate, hydrogen peroxide and t-butyl hydroperoxide also downregulate Sp1, Sp3 and Sp4 in cancer cell lines (15-17,38-41). We also observed that penfluridol targeted Sp TFs and pro-oncogenic Sp-regulated genes in vivo and this was consistent with potent inhibition of tumor growth in an orthotopic model (Fig. 7) and complemented results of previous studies on the anticancer activities of penfluridol (9,10).

This paper also demonstrates that penfluridol-mediated downregulation of α5-, α6-, β1 and β4-integrins is also ROS-dependent and Sp TFs regulate expression of these genes in breast cancer cell lines. Moreover, like β1- and β3-integrin (11), the α5-, α6- and β4-integrins are coregulated by NR4A1 and expression of this family of integrins is due to interactions of the NR4A1-Sp complex with their corresponding GC-rich gene promoter elements (Fig. 6G). Penfluridol does not exhibit NR4A1 antagonist activity but targets the integrins through repression of Sp TFs, whereas the C-
DIM/NR4A1 antagonists inactivate the coactivator-like activity of NR4A1 (Fig. 6F). Nuclear receptor-mediated activation of genes through interaction with DNA bound Sp TFs has been observed for several other receptors (42) and like the integrins in this study can be targeted through inactivation of the receptor or downregulation of Sp TFs. The identification of the mechanism of action of penfluridol coupled with the reported effectiveness of this compound as an inhibitor of breast cancer metastasis will facilitate the design of future clinical applications of this ROS inducer for breast cancer therapy. This would also include applications in treating tumors such as rhabdomyosarcomas which exhibit high endogenous ROS levels (9,43,44).
LITERATURE CITED


15. Chadalapaka G, Jutooru I, Safe S. Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells. Carcinogenesis 2012;33:886-94.


36. Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Devedec SE, et al. β1 Integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB


FIGURE CAPTIONS

Figure 1. Penfluridol induces ROS and ROS-dependent responses in breast cancer cells. (A) MDA-MB-231 and SKBR3 cells were treated with DMSO, 2.5 or 5.0 μM penfluridol alone, or in combination with 5 mM GSH for 3 hr, and ROS activity was determined as outlined in the Materials and Methods. The cells were treated as outlined above for 24 hr and effects on cell proliferation (B), Annexin V staining (C), and migration (D) in a Boyden chamber assay were determined as outlined in the Materials and Methods. Results are expressed as means ± SE for 3 replicates for each data points and significant (p<0.05) modulation by penfluridol (*) and reversal by GSH (**) are indicated.

Figure 2. Penfluridol induces ROS-dependent modulation of Sp1, Sp3, Sp4 and other responses in breast cancer cells. MDA-MB-231 and SKBR3 cells were treated with different concentrations of penfluridol alone or in combination with GSH for 24 hr, and whole cell lysates were analyzed for Sp1, Sp3 and Sp4 (A and B, respectively) and other responses (C and D, respectively) as outlined in the Materials and Methods. (E) Penfluridol-mediated downregulation of Sp proteins was also determined in the presence or absence of catalase by western blots of whole cell lysates. (F) MDA-MB-231 and SKBR3 cells were transfected with pGL3-GC3-luc and luciferase was determined as described (22).

Figure 3. Mechanism of penfluridol-induced Sp downregulation. (A) Molecular mechanism of drug-induced ROS and ROS effects on miR-ZBTB interactions and Sp
downregulation (14). MDA-MB-231 and SKBR3 cells were treated with penfluridol alone or in combination with GSH for 24 hr (B) or penfluridol alone for different times (C), and whole cell lysates were analyzed by western blots as outlined in the Materials and Methods. (D) Cells were treated with 5 μM penfluridol, and effects on interaction with the proximal GC-rich cMyc promoter were by ChIP assays as outlined in the Materials and Methods. (E) Cells were treated as outlined in (B) and expression of microRNAs (miRs) was determined by real time PCR. Penfluridol significantly (p<0.05) decreased all miRs and GSH significantly reversed these responses. (F) Cells were treated as outlined in (B) and expression of ZBTB10 and ZBTB4 were determined by western blot analysis as outlined in the Materials and Methods.

**Figure 4.** Penfluridol targets integrin expression via an ROS-cMyc (downregulation) pathway. MDA-MB-231 (A) and SKBR3 (B) cells were treated with penfluridol alone or in combination with GSH, and whole cell lysates were analyzed by western blots. Cells were transfected with oligonucleotides specifically targeted to Sp transcription factors [MDA-MB-231(C) and SKBR3 (D)] or cMyc (E and F), and whole cell lysates were analyzed by western blots. Whole cell lysates obtained after Sp knockdown in MDA-MB-231 and SKBR3 cells were generated in a previous study which also reports effects of these oligonucleotides on Sp1, Sp3 and Sp4 expression (C and D) (12).

**Figure 5.** Penfluridol decreases interactions of Sp proteins and other nuclear factors with integrin gene promoters. (A) Outline of GC-rich regions for α6-integrin (ITGA6), β4-integrin (ITGB4), α5-integrin (ITGA5) and β1-integrin (ITGB1) gene promoters and
primers targeting these regions. Breast cancer cells were treated with DMSO and 5 μM penfluridol, and interactions of Sp1, Sp3, Sp4 and other nuclear cofactors with the ITGA6 (B), ITGB4 (C), ITGA5 (D) and ITGB1 (E) gene promoters were determined in a ChIP assay as outlined in the Materials and Methods.

Figure 6. Integrin genes targeted by penfluridol are coregulated by Sp transcription factors and NR4A1. Breast cancer cells were transfected with siNR4A1 (A) or treated with the NR4A1 antagonists DIM-C-pPhOH (C-DIM8) and DIM-C-pPhCO₂Me (C-DIM14) (B), and whole cell lysates were analyzed by western blots. Breast cancer cells were treated with DMSO and the two NR4A1 antagonists, and interactions of Sp1, Sp3, Sp4 and other nuclear cofactors with the ITGA6 (C), ITGB4 (D) and ITGA5 (E) gene promoters were determined in a ChIP assay. The same interactions with the ITGB1 promoter were previously reported (11). (F) Model of NR4A1/Sp interactions with GC-rich integrin gene promoters and the differential targeting by penfluridol and NR4A1 antagonists.

Figure 7. Penfluridol inhibits tumor growth in vivo. Penfluridol (10 mg/kg/day) inhibit tumor volume (A) and weight (B) in athymic nude mice bearing MDA-MB-231 cells in an orthotopic model. Western blot analysis of tumor lysates (C) and quantitation of various proteins (D and E) where control proteins normalized to β-actin were set at 100% and penfluridol-mediated changes (normalized to β-actin) compared to controls were determined as outlined in the Materials and Methods. Both high and low molecular weight forms of Sp3 were detected.
**Figure 1**

A. MDA-MB-231 and SKBR3 cell lines were treated with different concentrations of Penfluridol (0, 2.5, and 5 μM) in the presence or absence of GSH (-GSH and +GSH) for 3 and 6 hours. The fold ROS induction was measured and compared.

B. The cell number of MDA-MB-231 and SKBR3 cells was assessed after treatment with Penfluridol (0, 1, 2.5, and 5 μM) in the presence or absence of GSH (-GSH and +GSH).

C. Relative green fluorescence was measured to determine the effect of Penfluridol on MDA-MB-231 and SKBR3 cells in the presence or absence of GSH (-GSH and +GSH).

D. Cell migration of MDA-MB-231 and SKBR3 cells was analyzed after treatment with Penfluridol (0, 1, 2.5, and 5 μM) in the presence or absence of GSH (-GSH and +GSH).
Figure 2

A) MDA-MB-231

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>0</th>
<th>2.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH (5 mM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sp1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sp3</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sp4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

B) SKBR3

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>0</th>
<th>2.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH (5 mM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sp1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sp3</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sp4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

C) MDA-MB-231

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>DMSO 2.5</th>
<th>DMSO 5.0</th>
<th>DMSO 7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH (5 mM)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-FAK</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>FAK</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-Caspase3</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>c-PARP</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

D) SKBR3

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>DMSO 5.0</th>
<th>DMSO 7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH (5 mM)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>p-FAK</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>FAK</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>c-Caspase3</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>c-PARP</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

E) MDA-MB-231

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>0</th>
<th>2.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalase (2KU)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sp1</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sp3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sp4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

F) SKBR3

<table>
<thead>
<tr>
<th>Penfluridol (μM)</th>
<th>0</th>
<th>2.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalase (2KU)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sp1</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sp3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sp4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>β-actin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

F) Luciferase Induction (%)

- DMSO
- Penfluridol (5 μM)
Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors

Erik Hedrick, Xi Li and Stephen Safe

Mol Cancer Ther Published OnlineFirst November 3, 2016.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-16-0451

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2016/11/03/1535-7163.MCT-16-0451.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/early/2016/11/03/1535-7163.MCT-16-0451. Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.